Treatment of experimental hepatic fibrosis by combinational delivery of urokinase‐type plasminogen activator and hepatocyte growth factor genes

• DOI: 10.1111/j.1478-3231.2005.01098.x
• Publication Date: 2005-07-05T18:53:21Z
• Authors: Yong Lin; Wei‐Fen Xie; Yue‐Xiang Chen; Xin Zhang; Xin Zeng; Hui Qiang; Wei‐Zhong Chen; Xiu‐Jiang Yang; Ze‐Guang Han; Zhong‐Bing Zhang
• Keywords: Hepatic stellate cell; Hepatic fibrosis

Abstract: Purpose: To investigate the effect of combinational delivery urokinase‐type plasminogen activator (uPA) and hepatocyte growth factor (HGF) genes on hepatic fibrosis. Methods: Replication‐deficient adenoviral vectors expressing either human HGF (AdHGF) or uPA (AduPA) were generated. gene was transferred into primary cultured hepatocytes to stellate cell (HSC) biological character cells. Combinational adenoviruses infused fibrosis rats. Serum markers as well histological immunohistochemical examination carried out test reversal Results: Transfection exogenous induced expression c‐met/HGF receptor stimulated proliferation. delivered HSC decreased amount collagen types I III accompanied with increased matrix metalloproteinase‐2. In vivo , area extracellular in fibrotic liver 72% AdHGF‐treated rats ( P <0.01), 64% AduPA‐treated group 51% bi‐genes transfection compared that controls. Moreover, staining revealed exerted more than mono‐gene transfection. Conclusions: Our study indicated simultaneous two antifibrotic could confer synergistic